Exemplis Discimus 2006, 150(1):13-23

Mauris ligula eros, condimentum vel, malesuada ac, sollicitudin in, urna.

Ken Gyylla, Lorenza Duvala, Vifi Cridmeenb, Desda Ktrameb
a Laboratory of Internal Medicine, Ord Mantell University, Yavin Republic
b Faculty of Vascular surgery, Abrion University, Geonosis Republic
1st Clinic of Radiotherapy, Raioballo Faculty Hospital, Republic of Kashyyyk

Morbi tortor est, placerat ac, commodo vel, ultricies ac, urna. Fusce elit turpis, lacinia tristique, aliquet sit amet, blandit dictum, neque. Curabitur ante augue, pretium euismod, porta eget, hendrerit at, neque. Donec sit amet sapien vel nunc malesuada rhoncus. Integer nibh ante, consectetuer nec, condimentum accumsan, facilisis nec, ipsum. Maecenas mi dolor, ultricies sit amet, tincidunt nec, condimentum sed, libero. Cras urna felis, rhoncus eu, dictum quis, blandit non, enim. Nam ante turpis, pulvinar et, gravida sit amet, adipiscing vitae, magna.

Keywords: Proin at libero, Maecenas justo, Cras sit amet leo, Sed tincidunt, Suspendisse a sem, Duis posuere

Received: April 4, 2006; Accepted: May 16, 2006; Published: July 1, 2006 

Open full article

References

  1. Dalton LK, Demerac S, Elmes BC, Loder JW, Swan JM, Teitei T. (1967) Synthesis of the tumor-inhibitory alkaloids, ellipticine, 9-methoxyellipticine, and related pyrido-[4,3-b]carbazoles. Aust J Chem 20, 27152727. Go to original source...
  2. .Rouesse JG, Le Chevalier T, Caille F, Mondesir JM., Sancho- Gamier H., May-Levin F Spielman M, DeJager R, Amiel JL.(1985) Phase II study of ellipticinium in advanced breast cancer. Cancer Treat Rep 69, 707708.
  3. Mathe G, Triana K, Pontiggia P, Blanquet D, Hallard M, Morette C. (1998) Data of pre-clinical and early clinical trials of acriflavine and hydroxy-methyl-ellipticine reviewed, enriched by the experience of their use for 18 months to 6 years in combination with other HIV1 virostatic. Biomed Pharmacother 52, 391396. Go to original source...
  4. Goodwin S, Smith AF, Horning EC. (1959) Alkaloids of Ochrosia elliptica Labill. J Am Chem Soc 81, 19031908. Go to original source...
  5. Auclair C. (1987) Multimodal action of antitumor agents on DNA: The ellipticine series. Arch Biochem Biophys 259, 114. Go to original source... Go to PubMed...
  6. Boyd MR.(1989) Status of the NCI preclinical antitumor drug discovery screen: Implications for selection of new agents for clinical trials. In: DeVita VT Jr, Hellman S and Rosenburg S, Editors. Cancer: Principles and Practice of Oncology Updates. vol. 3, Philadelphia: Lippincott, p. 112.
  7. Boyd MR. (1993) The future of drug development. In: Niederhuber JE, Editor. Current Therapy in Oncology. Philadephia: B.C. Decker, p. 1122.
  8. Acton EM, Narayanan VL, Risbood PA, Shoemaker PH, Vistica DT, Boyd MR. (1994) Anticancer specificity of some ellipticinium salts against human brain tumors in vitro. J Med Chem 37, 21852189. Go to original source... Go to PubMed...
  9. Arguello F, Alexander MA, Greene JF Jr, Stinson SF, Jorden JL, Smith EM, Kalavar NT, Alvord WG, Klabansky RL, Sausville EA. (1998) Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs to treatment of human brain tumor xenografts. J Cancer Res Clin Oncol 124, 1926. Go to original source... Go to PubMed...
  10. DeMarini DM, Abu-Shakra A, Gupta R, Hendee LJ, Levine JG. (1992) Molecular analysis of mutations induced by the intercalating agent ellipticine at the hisD3052 allele of Salmonella typhimurium TA98. Environ Mol Mutagenesis 20, 1218. Go to original source... Go to PubMed...
  11. Singh MP, Hill GC, Peoch D, Rayner B, Inabach JL, Lown JW. (1994) High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry 33, 1027110285. Go to original source...
  12. Chu Y, Hsu MT. (1992) Ellipticine increases the superhelical density of intracellular SV40 DNA by intercalation. Nucleic Acids Res 20, 40334038. Go to original source... Go to PubMed...
  13. Monnot M, Mauffret O, Simon V, Lescot E, Psaume B, Saucier JM, Charra M, Belehradek JJr, Fermandjian S. (1991) DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J Biol Chem 25, 18201829.
  14. Fossé P, René B, Charra M, Paoletti C, Saucier JM. (1992) Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationships. Mol Pharmacol 42, 590595. Go to PubMed...
  15. Froelich-Ammon SJ, Patchan MW, Osheroff N, Thompson RB. (1995) Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J Biol Chem 270, 149981504. Go to original source...
  16. Peng Y, Li C, Chen L, Sebti S, Chen J. (2003) Rescue of mutant p53 transcription function of ellipticine. Oncogene 22, 4478 4487. Go to original source...
  17. Sugikawa E, Hosoi T, Yazaki N, Gamanuma N, Nakanishi N, Ohashi M. (1999) Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. Anticancer Res 19, 30993108.
  18. Ohashi M, Sugikawa E, Nakanishi N. (1995) Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: A possible anticancer mechanism. Jpn J Cancer Res 86, 819829. Go to original source...
  19. Kuo PL, Hsu Y, Chang C, Lin C. (2005) The mechanism of ellipticine- induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett 223, 293301. Go to original source... Go to PubMed...
  20. Schwaller MA, Allard B, Lescot E and Moreau F. (1995) Protonophoric activity of ellipticine and isomers across the energy- transducing membrane of mitochondria. J Biol Chem 270, 2270922713. Go to original source...
  21. Hagg M, Berndtsson M, Mandic A, Zhou R, Shoshan MC, Linder S. (2004) Induction of endoplasmic reticulum stress by ellipticine plant alkaloids. Mol Cancer Ther 3, 489497. Go to PubMed...
  22. Stiborová M, Bieler CA, Wiessler M, Frei E. (2001) The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol 62, 675684. Go to original source... Go to PubMed...
  23. Frei E, Bieler CA, Arlt VM, Wiessler M, Stiborová M. (2002) Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem Pharmacol 64, 289295. Go to original source... Go to PubMed...
  24. Stiborová M, Stiborová-Rupertová M, Boĝek-Dohalská L, Wiessler M, Frei E. (2003) Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem Res Toxicol 16, 3847. Go to original source... Go to PubMed...
  25. Stiborová M, Breuer A, Aimová D, Stiborová-Rupertová M, Wiessler M, Frei E. (2003) DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P-postlabeling. Int J Cancer 107, 885890. Go to original source... Go to PubMed...
  26. Boĝek-Dohalská L, Frei E, Stiborová M. (2004) DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells. Collect Czech Chem Commun 69, 603615. Go to original source...
  27. Stiborová M, Sejbal J, Boĝek-Dohalská L, Aimová D, Poljaková J, Forsterová K, Rupertová M, Wiesner J, Hudeèek J, Wiessler M, Frei E. (2004) The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. Cancer Res 64, 83748380. Go to original source... Go to PubMed...
  28. Poljaková J, Stiborová M. (2004) Peroxidase-mediated ellipticine- DNA adduct formation explains the selective efficiency of this anticancer drug against breast cancer and leukemia. Chem Listy 98, 298.
  29. Poljaková J, Forsterová K, İulc M, Frei E, Stiborová M. (2005) Oxidation of ellipticine by peroxidases. Biomed Papers 149, 449 453. Go to original source...
  30. Stiborova M, Poljakova J, Ryslava H, Dracinsky M, Eckschlager T, Frei E. (2006) Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. Int J Cancer, submitted.
  31. Stiborova M, Borek-Dohalska l, Aimova D, Kotrbova V, Kukackova K, Janouchova K, Rupertova M, Ryslava H, Hudecek J, Frei E. (2006) Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes similarity between human and rat systems. Gen Physiol Biophys, in press.
  32. Rendic S, DiCarlo FJ. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29: 41380. Go to original source... Go to PubMed...
  33. Stiborová M, Rupertová M, Hodek P, Frei E, Schmeiser HH. (2004) Monitoring of DNA adducts in humans and 32P-postlabelling methods. A review. Collect Czech Chem Commun 69, 477498. Go to original source...
  34. Murray GI., Weaver RJ, Paterson PJ, Ewen SW, Melvin WT, Burke MD. (1993) Expression of xenobiotic metabolizing enzymes in breast cancer. J Pathol 169, 347353. Go to original source... Go to PubMed...
  35. Murray GI, Melvin WT, Burke M. Cytochrome P450 expression in tumors. (1995) J Pathol 176, 323324.
  36. Patterson LH, McKeown SR, Robson T, Gallagher R, Raleigh SM, Orr S. Antitumor prodrug development using cytochrome P450 (CYP) mediated activation. Anti-Cancer Drug Design 1999;14:47386.
  37. El-Rayes BF, Ali S, Heilbrun LK, Lababidi S, Bouwman S, Vischer D, Philip PA. (2003) Cytochrome P450 and glutathione transferase expression in human breast cancer. Clin Cancer Res 9, 17051709.
  38. Rekha GK, Sladek NE. (1997) Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics. Cancer Chemother Pharmacol 40, 215224. Go to original source... Go to PubMed...
  39. Ivy SP, Tulpule A, Fairchild CR, Averbuch SD, Myers CE, Nebert DW, Baird WM, Cowan KH. (1988) Altered regulation of P-450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line. J Biol Chem 263, 1911919125.
  40. Hofle G, Glase N, Leibold T, Sefkow M. Epothilone A-D and their thiazole-modified analogs as novel anticancer agents. Pure Appl Chem 1999; 71: 201924. Go to original source...
  41. Nicolaou KC, Ritzén A, Namoto K. (2001) Recent developments in the chemistry, biology and medicine of the epothilones. Chem Commun 15231535.
  42. Schlaifer D, Meyer K, Muller C, Attal M, Smith MT, Tamaki S, Weimels J, Pris J, Jaffrezou JP, Laurent G, Myers CE. (1994) Antisense inhibition of myeloperoxidase increases the sensitivity of the HL-60 cell line to vincristine. Leukemia 8, 289291.
  43. Lûbbert M, Miller CW, Koeffler HP. (1991) Changes of DNA methylation and chromatin structure in the human myeloperoxidase gene during myeloid differentiation. Blood 78, 345356.
  44. Hoy A, Leininger-Muller B, Jolivalt C, Siest G. (2000) Effect of apolipoprotein E on cell viability in a human neuroblastoma cell line: influence of oxidation and lipid-association. Neurosci Lett 285, 173176 Go to original source... Go to PubMed...
  45. Kirschenbaum A, Klausner AP, Lee R, Unger P., Yao S., Kiu X.H.,.Levine A.C. (2000) Expression of cyclooxygenase-1 and cyclooxygenase- 2 in the human prostate. Urology 56, 671676. Go to original source... Go to PubMed...
  46. Williams JA, Phillips DH. (2000) Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. Cancer Res 60, 46674677.
  47. Soslow RA, Dannenberg AJ, Rush D, Woemer B.M., Khan KM, Masferrerer J., Koki AT. (2000) COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89, 26372645. Go to original source...
  48. Matsuo M, Yonemitsu N, Zaitsu M, Ishii K, Hamasaki Y, Fukuyama K, Tabuchi K, Miyazaki S. (2001) Expression of prostaglandin H synthase-2 in human brain tumors. Acta Neuropathol 102, 181 187.
  49. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. (2001) Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res 61, 43754381. Go to PubMed...
  50. Peng JP, Su CY, Chang HC, Chai CY, Hung WC. (2002) Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx. Human Pathol 33, 100104. Go to original source... Go to PubMed...
  51. Castilla EA, Prayson RA, Kanner AA, Rybicky LA., Tubbs R.R., Vogelbaum M.A., Barnett G.H. (2003) Cyclooxygenase-2 in oligodendroglial neoplasms. Cancer 8, 14651472. Go to original source... Go to PubMed...
  52. Ludwig-Muller J, Tokalov SV, Franz A, Gutzeit HO. (2005) Quercetin metabolism in vital and apoptotic human leukaemia cells. Biol Chem 386, 279283. Go to original source... Go to PubMed...
  53. Schmelz K, Sattler N, Wagner M, Lûbbert M, Dorken B, Tamm I. (2005) Induction of gene expression by 5-aza-2-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DANN-methylation-dependent and independent mechanisms. Leukemia 19, 103111. Go to original source... Go to PubMed...
  54. Auclair C, Dugué B, Meunier B, Paoletti C. (1986) Peroxidasecatalyzed covalent binding of the antitumor drug N2-methyl-9-hydroxyellipticinium to DNA in vitro. Biochemistry 25, 1240-1245. Go to original source... Go to PubMed...
  55. Dugué B, Auclair C, Meunier B. (1986) Covalent binding of elliptinium acetate (NSC 264137) to nucleic acids of L1210 cells in culture. Cancer Res 46, 38283833. Go to PubMed...
  56. Dugue B, Paoletti C, Meunier B. (1984) Covalent binding of antitumor agent N2-methyl-9-hydroxy-ellipticinium acetate (NSC 264137) on RNA and poly A in vitro. Biochem Biophys Res Commun 124, 416422. Go to original source... Go to PubMed...
  57. Bernadou J, Meunier G, Paoletti C, Meunier B. (1983) Orthoquinone formation in the biochemical oxidation of the anti-tumor drug N2-methyl-9-hydroxyellipticinium acetate. J Med Chem 26, 574579. Go to original source... Go to PubMed...
  58. Meunier G, Meunier B. (1985) Peroxidase-catalyzed O-demethylation reactions quinone-imine fromation from 9-methoxyellipticine derivatives. J Biol Chem 260, 1057610582.
  59. Meunier G, Demontauzon D, Bernandou J, Grassy G, Bonnafous M, Cros S, Meunier B. (1988) The biooxidation of cyto-toxic ellipticine derivatives a key to structure-activity relationship studies. Mol Pharmacol 33, 93102. Go to PubMed...
  60. Bernadou J, Bonnafous M, Labat G, Loiseau P, Meunier B. (1991) Model systems for metabolism studies biomimetic oxidation of acetaminophen and ellipticine derivatives with water-soluble metalloporphyrins associated to potassium monopersulfate. Drug Metab Dispos 19, 360365. Go to PubMed...
  61. Pratviel G, Bernadou J, Ha T, Meunier G, Cros S., Meunier B, Gillet B, Guitret E. (1986) Ribose as the preferential target for the oxidized form of elliptinium acetate in ribonucleos(t)ides biological-activities of the resulting adducts. J Med Chem 20, 13501355. Go to original source... Go to PubMed...
  62. Kansal VK, Funakoshi S, Mangeney P, Gillet B, Guittet E, Lallemand JY, Potier P. (1985) Interaction of nucleosides with antitumoral agents 9-hydroxy-N2-methylellipticinium acetate and 9-hydroxy-N2-methylolivacinium acetate. Tetrahedron 41, 5107 5120. Go to original source...
  63. Kansal VK, Potier P, Gillet B, Guittet E, Lallemand J-Y, Huynh- Dinh T, Igolen J. (1985) Regioselective and stereoselective alkylation at the 3-terminal end of ribonucleotides by N2-methyl- 9-hydroxyellipticinium acetate an antitumor agent. Tetrahedron Lett 26, 28912894. Go to original source...
  64. Donaghy MJ, Stanforch SP. (1999) Nucleophilic addition of fused benzimidazole N-oxide. Tetrahedron 55, 14411448. Go to original source...
  65. Josephy PD. (1996) The role of peroxidase-catalyzed activation of aromatic amines in breast cancer. Mutagenesis 11, 37. Go to original source... Go to PubMed...
  66. Gorlewska-Roberts KM, Teitel CH, Lay JO, Roberts DW, Kadlubar FF. (2004) Lactoperoxidase-catalyzed activation of carcinogenic aromatic and heterocyclic amines. Chem Res Toxicol 17, 1659 1666. Go to original source...
  67. Yha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. (2004) Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215, 120.
  68. Noguchi N, Nakano K, Aratani Y, Koyama H, Kodama T, Niki E. J. (2000) The role of myeloperoxidase in neutrophil-induced oxidation of low density lipoprotein as studied by myeloperoxidaseknockout mouse. Biochem. (Tokyo) 127, 971977. Go to original source... Go to PubMed...

Return to the content